Kay Tanaka, Yale Univ. Sch. of Med., Dept. of Human Genetics, New Haven, Conn. (Intr. by Sydney S. Gellis).
The question of whether Vitamin B12 can prevent fetal accumulation of methylmalonic acid (MMA) in the vitamin-responsive form of the disease was investigated for the first time. During the second pregnancy of a woman who had previously lost a child with presumed MMA-emia, sonicated amniotic fluid cells initially showed no activity of MM-CoA Mutase and no accumulation of the coenzyme 5'-deoxyadenosylcobalamin. Full activity of the enzyme was restored with the addition of this cofactor. Vitamin B12 in large doses was given to the mother from 32 wks. gestation to term. Maternal serum B12 levels reached 3,000-6,000 pglml (normal < 900) in the last 6 weeks. C o~d blood B12 was over 19,000 pg/ml; maternal serum B12 taken simultaneously measured over 18,000. Instead of the anticipated progressive increase in maternal urinary MMA during the last 2 months of pregnancy, there was a decrease. Following birth, the infant's urinary MMA content was 67&gm/mg creatinine (normal < 5.0), and has remained essentially the same for the first 5 weeks of life on a diet containing 1.5 gm protein/Kg/day; thus far supplemental B12 has not been necessary. Skin biopsy studies to confirm B12 responsiveness are nearing completion. It seems likely that administration of large doses of Vitamin B12 to mothers carrying fetuses with the B12 responsive form of MMAemia can slow prenatal accumulation of MMA. Globin messenger RNA ( W A ) from reticulocytes of several patients with various 6-thal syndromes was studied in two ways: I. partially purified globin mRNA preparations from Bthal reticulocytes were tested for their capacity to promote a and BA globin chain synthesis in a heterologous cell-free system which preferentially synthesized BA chains when incubated with normal human globin -A (BA/u = 2-4). In this system, globin mRNA preparations from each of 10 patients with B*-thal (BA/a = 0.1-0.3); 2 patients with homozygous B0-thal (BA/u = 0); and 4 patients doubly heterozygous for B0-thal and an abnormal hemogloliin (BA/a = 0) reproduced in every case the defect in B chain synthesis occurring in their intact reticulocytes. 11. The actual chemical amounts of B chain specific mRNA sequences (relative to a chain sequences) in the B-thal mRNA's were measured by re-annealing B-thal mRNA, in separate experiments, with synthetic radioactive DNA (cDNA) complementary to purified normal u chain specific or 6 chain specific mRNA.
MOLECULAR GENETICS OF THE
When measured by these hybridization techniques, B chain mRNA was reduced to 10-309 of normal in the 4 patients tested with B+-thal and was absent in 4 patients with 0'-thal. All of the 6-thal syndromes studied to date are thus characterized by B chain mRNA which is diminished (a+-thal) or absent (B0-thal) not only in terms of template activity but also in absolute chemical amounts.
HYBRIDIZATION OF ESTABLISHED IMMLlNOGLOBULIN-PRODUCING CELLS. Arthur D. Bloom, Anita S. Wong, and Frank T. Nakamura. Univ. of Mich. Med. Sch., Depts. of Human Genetics and Ped.
To study the regulation of immunoglobulin (Ig) production in human lymphocytes and to link the genes for heavy and light chain synthesis to specific human chromosomes, we have developed methods for hybridization of the cells of established lymphocyte lines. Cur first fusion involved an interspecific human lymphocyte (HGPRT-, kappa chain producing) x hamster fibroblast (TK-) cross; the second, an intraspecific human lymphocyte x lymphocyte cross, with both lines producers of garmna, mu, and kappa chains. In both instances, the lymphocytes were pre-treated with 0.01% trypsin prior to addition of Sendai virus. In the interspecific cross, kappa chain production was lost; in the intraspecific cross, in which the chromosomes of both parental cells were initially retained, gamma, mu, and kappa chain production were also retained, as determined by immunofluorescence. The lines resulting from the lymphocyte x lymphocyte hybridization were, however, unstable, and reverted to diploidy by 8 weeks post-fusion. We are currently attempting to establish and maintain a chromosomally stable intraspecific hybrid obtained from fusion of an and an Ig-cell line. and from NL values (p 0.01). Conclusions: (1) HMG CoA reductase levels were not inhibited by serum in cells from 3 patients with HHLPII, which confirms and extends to new patients the observation of Goldstein et al. (PNAS 70:2804 , 1973 . (2) Genotypic variation is suggested by one patient, LH, a phenotypic HHLPII, who exhibited partial inhibition by FCS.
NIEMANN-PICK DISEASE, TYPE C: ABSENCE OF A SPHINGOMYELINASE ISOENZYME. John W. Callahan, Mary Khalil and J. Alexander Lowden. Research Inst., The Hosp. for Sick Children, Toronto, Canada.
Niemann-Pick disease exists in multiple forms. Two types (A and B) are characterized by sphingmyelin storage and markedly reduced levels of sphingomyelinase activity. A third form (Type C) also shows sphingomyelin storage but total enzyme activity is within normal limits. Since defects in multiple enzyme species could explain this data, extracts of human liver were subjected to isoelectric focusing in sucrose gradients (pH range 4-7). Two major (I and 11) and two minor (111 and IV) species of sphingmyelinase were resolved in normal liver. Recovery of enzyme activity was 70-80%. Isoenzyme I has a pI of 4.5-4.7, a pH optimum near 5.0 and a Km of 0.069 nM. The second major species (11) has a p1 of 5.1-5.3, a pH optimum near 4.0 and a Km of 0.045 nt-l at pH 4.0. Both species are found at the corresponding isoelectric point when re-focused separately. Species 111 and IV have not been characterized. In liver from a known case of Niemann-Pick Type C, only one major isoenzyme (PI 4.6) was found. It refocused to the same isoelectric point and showed the same properties as isoenzyme I from normal liver. In preliminary experiments on brain, isoenzyme I was the major species present. We conclude that multiple species of sphingmyelinase exist in human tissues and the absence of species I1 in liver constitutes thegeneticdefect in Type C, Niemann-Pick disease. Supported by Provincial Health Grant PR 360C.
